Syntegon delivered a record financial performance in 2025, underscoring the strength of its positioning across the pharmaceutical, biotech and food industries, while signaling further growth ambitions for the year ahead.
The company reported a 10% increase in revenue to EUR 1.75 billion, alongside order intake of EUR 1.86 billion, providing strong visibility into 2026. Growth was particularly pronounced in its pharmaceutical segment, where sales rose 22%, reflecting sustained demand in structurally expanding end markets.
Profitability also improved markedly. Earnings before interest, taxes, depreciation and amortization climbed 27% to EUR 282 million, with the EBITDA margin reaching 16.1%, up 210 basis points from the previous year. The gains were driven by higher volumes in more profitable segments, operational efficiencies and disciplined cost management, as well as improvements in project execution. Strategic adjustments to the company’s global manufacturing footprint, including the establishment of an engineering hub in India, further supported margin expansion.
Free cash flow increased 51% to EUR 196 million, exceeding an already strong level in 2024. The company attributed the rise to robust earnings growth, a lean capital expenditure approach and tighter working capital management.
The company also continued to invest in its long-term growth platform. In 2025, Syntegon expanded capacity and innovation capabilities, including the launch of a Business Excellence Center in Stuttgart and the opening of a new pharmaceutical solid-dose facility in Fellbach, Germany. It allocated EUR 56 million to research and development, focusing on next-generation production line solutions.
Within its food division, the company benefited from strong adoption of its SVX product platform, which has gained traction for its speed, flexibility and sustainability performance. At the same time, demand for service offerings continued to rise as customers sought to enhance efficiency through upgrades and advanced lifecycle support.
Innovation remained central to Syntegon’s strategy. A notable milestone in 2025 was the introduction of SynTiso, described as the world’s first gloveless high-speed filling line for liquid pharmaceuticals. The system is designed to reduce contamination risks while improving production efficiency, and has already attracted interest and initial orders from major pharmaceutical companies.
Sustainability efforts also gained recognition, with Syntegon receiving the EcoVadis Platinum Medal, placing it among the top-performing companies globally in environmental and social responsibility metrics.
Looking ahead to 2026, the company expects continued growth and improved financial results. With a strong installed base, expanding service business and ongoing investments in innovation, Syntegon is aiming to increase market share in resilient, mission-critical sectors. Expansion in the US market is expected to be a key priority, alongside execution of its longer-term Business Plan 2030, which focuses on scaling services, strengthening innovation leadership and advancing operational excellence.
Find out more at: https://www.syntegon.com/